News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Ariad Pharmaceuticals, Inc. to Receive $2.5 Million from Partner Merck & Co., Inc.
August 6, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CAMBRIDGE, Mass. (AP) -- Ariad Pharmaceuticals Inc. said Wednesday it will receive a $2.5 million payment from partner Merck & Co. for moving a cancer drug into midstage clinical trials.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Merck & Co.
MORE ON THIS TOPIC
Neurodegenerative disease
GSK abandons Alector after back-to-back neuro stumbles
July 9, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Tanabe pens deal to sell plants to Towa in post-buyout pivot
July 8, 2026
·
2 min read
·
Nick Paul Taylor
Manufacturing
Amgen recalls almost 1 million bottles of heart failure drug over quality issue
July 8, 2026
·
1 min read
·
Nick Paul Taylor
Layoff Tracker
Novartis cuts New Jersey workforce again, ousting 322 employees
July 8, 2026
·
67 min read
·
BioSpace Editorial Staff
